Sinocare Technology (01302.HK): The G-BranchTM thoracoabdominal aortic endoprosthesis system has received official registration approval from the National Medical Products Administration.

Intelligence Finance APP News, Xianjian Technology (01302.HK) announced that on November 6, 2025, the G-BranchTM thoracoabdominal aortic endoprosthesis system (G-BranchTM or the product) jointly developed by Prof. Guo Wei's team from the First Medical Center of the PLA General Hospital of China and the Group has obtained official registration approval from the China National Medical Products Administration. This product is suitable for the treatment of thoracoabdominal aortic aneurysm (TAAA) involving the celiac trunk, superior mesenteric artery, and bilateral renal arteries, and can achieve complete intraluminal reconstruction of the thoracoabdominal aortic aneurysm.